Literature DB >> 16721172

Epidemiological impact of antidepressant and antipsychotic drugs on the general population.

Corrado Barbui1, Mauro Percudani.   

Abstract

PURPOSE OF REVIEW: To analyse the prevalence of and sex and age distribution associated with antidepressant and antipsychotic drug exposure in the general population and to highlight recent epidemiological findings concerning specific adverse outcomes associated with drug exposure. RECENT
FINDINGS: Epidemiological studies indicate high rates of second-generation antidepressant and antipsychotic drug use in the general population. The use is more prevalent among women than among men, and in older rather than in younger age groups. A new pattern of adverse outcomes has been described in individuals exposed to newer agents, including a possible risk of suicidal acts in adults receiving second-generation antidepressants, the risk of cerebrovascular events in older individuals receiving second-generation antipsychotics and the risk of metabolic disturbances in individuals exposed to specific second-generation antipsychotics.
SUMMARY: The assessment of, and attention to, the development of specific adverse reactions in individuals exposed to second-generation psychotropic drugs may improve treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721172     DOI: 10.1097/01.yco.0000228762.40979.8f

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  2 in total

1.  Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study.

Authors:  C-Y Wang; S-H Fu; C-L Wang; P-J Chen; F-L L Wu; F-Y Hsiao
Journal:  Osteoporos Int       Date:  2015-07-01       Impact factor: 4.507

2.  A qualitative exploration of depression in emerging adulthood: disorder, development, and social context.

Authors:  Sachiko A Kuwabara; Benjamin W Van Voorhees; Jackie K Gollan; G Caleb Alexander
Journal:  Gen Hosp Psychiatry       Date:  2007 Jul-Aug       Impact factor: 3.238

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.